Blog - Page 391 of 5643 - QualityStocks

TuesdaySep 24, 2024 9:45 am

Clene Inc. (NASDAQ: CLNN) to Discuss Lead Candidate CNM-Au8(R) Biomarker, Clinical Data for ALS with Food and Drug Administration Leadership

The company is seeking an accelerated approval regulatory pathway for CNM-Au8® for ALS. The FDA agreed to an in-person meeting to reevaluate Clene’s submission. Lead drug candidate CNM-Au8 has been shown to restore and protect neurological function, offering hope for patients with neurodegenerative conditions. The FDA meeting will be held before the end of November and will be attended by top FDA officials and key opinion leaders in ALS, biostatistics and biomarkers. Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative…

TuesdaySep 24, 2024 9:00 am

Platinum Group Metals Ltd. (NYSE American: PLG) (TSX: PTM) Subsidiary Positioned in Lithium-Sulfur Battery Space

New battery technologies are being researched and developed to rival lithium-ion batteries in terms of efficiency, cost and sustainability. Lithium-sulfur batteries could offer advantages over lithium-ion batteries, including increased range and storage capacity. Companies working in this space include Lion Battery Technologies Inc. founded by Platinum Group Metals Ltd. and Anglo American Platinum Limited. The battery of choice these days, relied on to power everything from digital devices to electric vehicles and even energy-storage systems, is the lithium-ion battery. However, lithium-ion technology has its drawbacks; consequently, other battery solutions are being developed, including lithium sulfur. Through its subsidiary Lion Battery,…

MondaySep 23, 2024 11:20 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation at the 24th Annual Biotech in Europe Forum

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that CEO John Climaco will present at the 24th Annual Biotech in Europe Forum. The presentation is scheduled for Wednesday, September 25, 2024, at 1:55 p.m. CEST in Basel, Switzerland. Additionally, management will participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference. To view the full press release, visit https://ibn.fm/KPZOu About CNS Pharmaceuticals Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing…

MondaySep 23, 2024 10:44 am

QualityStocksNewsBreaks – Dynasty Gold Corp.’s (TSX.V: DYG) (FSE: D5G1) (OTC: DGDCF) Initial Assay Results from 2024 Drill Program Demonstrate ‘Richness of the Gold System’ at Thundercloud

Dynasty Gold (TSX.V: DYG) (FSE: D5G1) (OTC: DGDCF), a Canadian mineral exploration company, today announced assay results for the first phase of the 2024 drill program at its Thundercloud property. The program comprises 2,198 meters. According to the announcement, drilling successfully intersected high-grade gold mineralization of 5.13 g/t Au over 18 meters from 97.5m to 115.5m, including 9.3 g/t Au over 4.5 meters and numerous 5 to 8+ g/t Au over 1.5m in drillhole TC24-02 (30 meters additional assay results are pending). In addition, drilling intersected broad zones of lower grade mineralization from 25 meters below surface with intercepts between…

MondaySep 23, 2024 9:45 am

2024 MoneyShow/TradersEXPO Orlando to Feature World-Class Money Experts

The 2024 MoneyShow/TradersEXPO Orlando will be held on Oct. 17-18 at the Omni Orlando Resort at ChampionsGate in Central Florida. The MoneyShow conference is an interactive platform for networking, education and collaborative experiences. Attendees will get valuable insights from money experts on personal portfolio management right before the U.S. presidential elections. Distinguished financial leaders will grace the conference stage to guide traders and investors with their experience and wisdom. MoneyShow has a 43-year history of offering expertise, connections and education, to active traders and investors, helping them best position their portfolios in all market environments. MoneyShow’s platform connects traders and…

MondaySep 23, 2024 9:00 am

Trillion Energy International Inc. (CSE: TCF) (OTCQB: TRLEF) Works to Meet Increased Energy Demand in Europe, Türkiye

Europe’s energy landscape has undergone significant changes recently, in part due to the geopolitical tensions between Russia and Ukraine. Türkiye’s energy demand is growing rapidly with an expanding economy and population. Amid this growth, Trillion Energy International has emerged as a significant player in the natural gas sector. The demand for natural gas in Europe and Türkiye is on the rise, driven by a combination of geopolitical, economic and environmental factors. As the world grapples with energy security and sustainability, natural gas has emerged as a crucial component of the energy mix in these regions. The increased demand for natural…

MondaySep 23, 2024 8:30 am

QualityStocksNewsBreaks – D-Wave Quantum Inc. (NYSE: QBTS) Announces Partnership with Staque to Accelerate Commercial Adoption of Quantum in the Middle East

D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software and services, and the world’s first commercial supplier of quantum computers, has announced its partnership with Staque, a leading consulting and development practice with a focus on artificial intelligence (“AI”), blockchain and quantum computing. According to the announcement, the two companies will work to“foster collaboration and usage of quantum computing solutions for optimization and AI applications.” The companies aim to accelerate the commercial adoption of annealing quantum computing across the Middle East. “We believe organizations must embrace today’s advanced technologies such as quantum computing and AI in…

MondaySep 23, 2024 8:30 am

QualityStocksNewsBreaks – AROYA Sponsors, Exhibits at Hall of Flowers Event, Open to the Public for First Time

AROYA, the leading cannabis cultivation platform, is a sponsor of the Hall of Flowers event in California and is exhibiting its state-of-the-art precision irrigation and cultivation technology at the event. The Hall of Flowers Market & Festival is slated for Sept. 21, 2024, in Sonoma, California, and is open to the public for the first time ever. According to the announcement, the company will have special product drops and offer exclusive deals for attendees, who will also be able to participate in demonstrations of the AROYA GO unit and interact with expert AROYA team members at the AROYA exhibit booth.…

FridaySep 20, 2024 3:30 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating ‘More Effective, Tolerable’ Oral Delivery of GLP-1 Drugs

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, looks to offer a better alternative to diabetes management and treatment through its patented DehydraTECH(TM) technology. “Lexaria has recently made strides with glucagon-like peptide-1 (‘GLP-1’) studies. It has reported positive interim results from an animal study on diabetes. This milestone best showcases the potential of its patented technology in not only addressing diabetes and obesity. Recently, the company announced the dosing completion of its human pilot study #2, GLP-1-H24-2, which sought to explore effective oral delivery of GLP-1 drugs. Some evaluated aspects included side effects, blood levels of…

FridaySep 20, 2024 2:30 pm

QualityStocksNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Stands Distinct from Industry Players with Buntanetap

Annovis Bio (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, secured U.S. patent No. 12,042,482 covering methods for treating traumatic brain injury (“TBI”) and nerve injury with buntanetap, the company’s lead drug candidate. “Buntanetap (formerly Posiphen) targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins such as amyloid beta, tau, alpha-synuclein, and TDP43; by inhibiting their translation, the drug improves synaptic transmission, axonal transport, reduces neuroinflammation, and prevents nerve cells from dying. Unlike monoclonal antibody therapies, buntanetap is an orally available small molecule that inhibits multiple neurotoxic proteins simultaneously, making it a promising solution…

Site Search

Company Search